Want to join the conversation?
Thompson Research Group analyst Kathryn Thompson questions $VMC how much of its strength was driven by the new funding initiatives. CEO Thomas Hill says that there is no flow through from the new outlay funding, which is healthy growth in Georgia. There is nothing from the new rail line at this point.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.